Krishna Institute of Medical Sciences Limited (NSE:KIMS)
India · Delayed Price · Currency is INR 726.00
-0.15 (-0.02%)
Nov 12, 2026, 3:29 PM IST
NSE:KIMS Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 45,962 | 39,046 | 30,351 | 24,982 | 21,977 | 16,508 |
| 45,962 | 39,046 | 30,351 | 24,982 | 21,977 | 16,508 | |
Revenue Growth | 35.12% | 28.65% | 21.49% | 13.68% | 33.13% | 24.13% |
Cost of Revenue | 18,536 | 15,915 | 12,128 | 10,160 | 8,793 | 6,676 |
Gross Profit | 27,426 | 23,131 | 18,223 | 14,822 | 13,184 | 9,832 |
Selling, General & Admin | 875 | 875 | 477 | 495 | 352.46 | 205.01 |
Other Operating Expenses | 17,639 | 14,215 | 9,910 | 7,950 | 6,784 | 4,429 |
Operating Expenses | 22,366 | 17,922 | 12,159 | 9,910 | 8,429 | 5,361 |
Operating Income | 5,060 | 5,209 | 6,064 | 4,912 | 4,755 | 4,471 |
Interest Expense | -2,680 | -1,967 | -887 | -464 | -293.18 | -159.21 |
Interest & Investment Income | 121 | 121 | 102 | 23 | 95.32 | 122.82 |
Earnings From Equity Investments | 32 | 26 | - | -3 | - | 95.1 |
Other Non Operating Income (Expenses) | 289 | 52 | 26 | 70 | 29.43 | 23.15 |
EBT Excluding Unusual Items | 2,822 | 3,441 | 5,305 | 4,538 | 4,586 | 4,553 |
Gain (Loss) on Sale of Investments | 5 | 5 | 48 | 41 | 30.01 | - |
Gain (Loss) on Sale of Assets | -5 | -5 | 109 | 4 | 6.1 | -27.17 |
Other Unusual Items | 33 | -102 | 119 | 12 | 226.72 | 42.41 |
Pretax Income | 2,855 | 3,339 | 5,581 | 4,595 | 4,849 | 4,569 |
Income Tax Expense | 885 | 919 | 1,433 | 1,236 | 1,191 | 1,131 |
Earnings From Continuing Operations | 1,970 | 2,420 | 4,148 | 3,359 | 3,658 | 3,438 |
Minority Interest in Earnings | 154 | -6 | -303 | -259 | -294.91 | -111.1 |
Net Income | 2,124 | 2,414 | 3,845 | 3,100 | 3,363 | 3,327 |
Net Income to Common | 2,124 | 2,414 | 3,845 | 3,100 | 3,363 | 3,327 |
Net Income Growth | -36.79% | -37.22% | 24.03% | -7.83% | 1.09% | 65.33% |
Shares Outstanding (Basic) | 406 | 400 | 400 | 400 | 400 | 397 |
Shares Outstanding (Diluted) | 406 | 400 | 400 | 400 | 400 | 397 |
Shares Change | 1.53% | - | - | - | 0.74% | 4.32% |
EPS (Basic) | 5.23 | 6.03 | 9.61 | 7.75 | 8.41 | 8.38 |
EPS (Diluted) | 5.23 | 6.03 | 9.61 | 7.75 | 8.41 | 8.38 |
EPS Growth | -37.77% | -37.25% | 24.03% | -7.83% | 0.35% | 58.51% |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | -7,575 | -9,171 | -4,271 | -1,261 | -1,424 | 1,537 |
Free Cash Flow Per Share | -18.65 | -22.92 | -10.67 | -3.15 | -3.56 | 3.87 |
Gross Margin | 59.67% | 59.24% | 60.04% | 59.33% | 59.99% | 59.56% |
Operating Margin | 11.01% | 13.34% | 19.98% | 19.66% | 21.63% | 27.09% |
Profit Margin | 4.62% | 6.18% | 12.67% | 12.41% | 15.30% | 20.15% |
Free Cash Flow Margin | -16.48% | -23.49% | -14.07% | -5.05% | -6.48% | 9.31% |
EBITDA | 8,425 | 7,554 | 7,544 | 6,199 | 5,828 | 5,120 |
EBITDA Margin | 18.33% | 19.35% | 24.86% | 24.81% | 26.52% | 31.01% |
D&A For EBITDA | 3,365 | 2,345 | 1,480 | 1,287 | 1,073 | 648.09 |
EBIT | 5,060 | 5,209 | 6,064 | 4,912 | 4,755 | 4,471 |
EBIT Margin | 11.01% | 13.34% | 19.98% | 19.66% | 21.63% | 27.09% |
Effective Tax Rate | 31.00% | 27.52% | 25.68% | 26.90% | 24.56% | 24.75% |
Revenue as Reported | 46,461 | 39,308 | 30,670 | 25,143 | 22,236 | 16,711 |
Advertising Expenses | - | 629 | 329 | 252 | 197.39 | 111.51 |